GSK scores major trial win with potential multiple myeloma b...

GlaxoSmithKline may have scored a major cancer trial win after its belantamab mafodotin hit targets in the pivotal DREAMM-2 trial in relapsed multiple myeloma.

GSK exits Ebola vaccine R&D as J&J rival starts Uganda trial

EU clears GSK’s asthma drug Nucala in patient-friendly forma...

Symonds confirmed as new GSK chairman amid CEO's business re...

GlaxoSmithKline has confirmed that it has hired Jonathan Symonds as chairman, confirming press speculation that the former Novartis and AstraZeneca finance chief was in the frame to replace

GSK takes aim at RA market, pitting otilimab against Pfizer ...

GlaxoSmithKline (GSK) has made a serious play for the lucrative rheumatoid arthritis (RA) drug market, announcing the beginning of a phase 3 development programme, involving a new class of

ViiV's Dovato HIV pill approved in EU

ViiV’s new daily HIV treatment has been approved in the EU, as the company aims to win over patients with a more convenient treatment approach.